Liquidia (NASDAQ:LQDA) CAO Dana Boyle Sells 1,581 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) CAO Dana Boyle sold 1,581 shares of the stock in a transaction that occurred on Monday, October 26th. The stock was sold at an average price of $43.19, for a total transaction of $68,283.39. Following the completion of the sale, the chief accounting officer directly owned 164,028 shares of the company’s stock, valued at $7,084,369.32. This trade represents a 0.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dana Boyle also recently made the following trade(s):

• On Monday, October 12th, Dana Boyle sold 5,892 shares of Liquidia stock. The stock was sold at an average price of $28.48, for a total transaction of $167,804.16.

Liquidia Stock Up 0.6%

LQDA traded up $0.28 on Wednesday, reaching $45.72. 2,235,400 shares of the company traded hands, compared to its average volume of 2,280,838. The stock’s 50 day moving average price is $54.69 and its 200-day moving average price is $54.15. Liquidia Corporation has a 52-week low of $22.05 and a 52-week high of $93.61. The company has a market cap of $4.09 billion, a price-to-earnings ratio of 33.37, a PEG ratio of 0.37 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.31 and a quick ratio of 2.12.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The company had revenue of $171.68 million during the quarter, compared to analyst estimates of $168.48 million. During the same quarter in the prior year, the company posted ($0.49) EPS. The firm’s quarterly revenue was up 1842.1% compared to the same quarter last year. On average, sell-side analysts expect that Liquidia Corporation will post 2.05 EPS for the current fiscal year.

Institutional Trading of Liquidia

A number of institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE grew its position in Liquidia by 18.7% in the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after acquiring an additional 360,372 shares in the last quarter. Eversept Partners LP raised its holdings in shares of Liquidia by 33.0% during the 1st quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock valued at $25,565,000 after purchasing an additional 167,949 shares in the last quarter. Pale Fire Capital SE raised its holdings in shares of Liquidia by 2.4% during the 1st quarter. Pale Fire Capital SE now owns 388,377 shares of the company’s stock valued at $14,657,000 after purchasing an additional 8,985 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Liquidia in the 2nd quarter valued at $29,694,000. Finally, Seven Fleet Capital Management LP lifted its stake in shares of Liquidia by 25.2% in the 2nd quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock valued at $20,459,000 after purchasing an additional 51,727 shares during the last quarter. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

LQDA has been the topic of several research analyst reports. Needham & Company LLC lowered their price target on shares of Liquidia from $72.00 to $58.00 and set a “buy” rating on the stock in a report on Wednesday, October 14th. BTIG Research raised Liquidia from a “neutral” rating to a “buy” rating and set a $70.00 price objective for the company in a research report on Wednesday, October 14th. Weiss Ratings raised Liquidia from a “sell (d-)” rating to a “hold (c)” rating in a research report on Tuesday, September 22nd. Raymond James Financial restated an “outperform” rating on shares of Liquidia in a research note on Thursday, October 8th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Liquidia in a research report on Thursday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $72.85.

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with pulmonary hypertension and other serious cardiopulmonary diseases. The company is headquartered in Research Triangle Park, North Carolina, and uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition for inhaled and injectable medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder formulation of treprostinil delivered through a proprietary inhaler.